GlassScriptPhysician profile
William H Long
NPI 1225090251
$1,008.20
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $210 · 2021: $169 · 2022: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.78 | 2019-2022 | |
| Pfizer INC. | $117.34 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.12 | 2019-2021 | |
| Minerva Surgical, INC | $95.12 | 2019-2020 | |
| Hologic Sales and Service, LLC | $78.08 | 2019-2022 | |
| Asensus Surgical, INC. | $74.66 | 2019 | |
| Coloplast Corp | $63.29 | 2019-2020 | |
| Therapeuticsmd, INC. | $44.07 | 2019-2020 | |
| Roche Diagnostics Corporation | $40.16 | 2019-2021 | |
| Myovant Sciences INC. | $32.98 | 2022 | |
| Lupin INC. | $27.04 | 2019-2021 | |
| Daiichi Sankyo INC. | $23.74 | 2020 | |
| Covidien LP | $21.69 | 2020 | |
| Duchesnay USA Incorporated | $15.59 | 2019 | |
| Allergan, INC. | $15.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $14.46 | 2019 | |
| Avion Pharmaceuticals | $13.28 | 2019 | |
| Millicent US INC | $13.04 | 2019 | |
| Exeltis, USA INC. | $12.23 | 2021 | |
| Agile Therapeutics, INC. | $12.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.